KD Logo

The Attractiveness of Investing In Harmony Biosciences Holdings Inc (HRMY) is Growing

Harmony Biosciences Holdings Inc’s filing revealed that its CHIEF COMMERCIAL OFFICER Dierks Jeffrey unloaded Company’s shares for reported $0.49 million on Jan 24 ’25. In the deal valued at $37.31 per share,13,125 shares were sold. As a result of this transaction, Dierks Jeffrey now holds 0 shares worth roughly $ 0.0.

Then, Dierks Jeffrey sold 1,629 shares, generating $61,941 in total proceeds. Upon selling the shares at $38.02, the CHIEF COMMERCIAL OFFICER now owns 0 shares.

Before that, Kapadia Sandip sold 1,775 shares. Harmony Biosciences Holdings Inc shares valued at $67,547 were divested by the CHIEF FINANCIAL OFFICER at a price of $38.05 per share. As a result of the transaction, Kapadia Sandip now holds 0 shares, worth roughly $0.0.

Deutsche Bank initiated its Harmony Biosciences Holdings Inc [HRMY] rating to a Buy in a research note published on February 11, 2025; the price target was $55. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in mid December with a ‘”a Buy”‘ rating. UBS started covering the stock on September 10, 2024. It rated HRMY as “a Buy”.

Price Performance Review of HRMY

On Tuesday, Harmony Biosciences Holdings Inc [NASDAQ:HRMY] saw its stock jump 0.28% to $39.09. Over the last five days, the stock has gained 2.90%. Harmony Biosciences Holdings Inc shares have risen nearly 13.60% since the year began. Nevertheless, the stocks have risen 15.34% over the past one year. While a 52-week high of $41.61 was reached on 01/21/25, a 52-week low of $28.14 was recorded on 01/10/25. SMA at 50 days reached $36.15, while 200 days put it at $34.23.

Levels Of Support And Resistance For HRMY Stock

The 24-hour chart illustrates a support level at 38.33, which if violated will result in even more drops to 37.57. On the upside, there is a resistance level at 39.68. A further resistance level may holdings at 40.26. The Relative Strength Index (RSI) on the 14-day chart is 58.80, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.40, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 30.64%. Stochastics %K at 66.89% indicates the stock is a holding.

The most recent change occurred on June 21, 2024 when Citigroup began covering the stock and recommended ‘”a Buy”‘ rating along with a $48 price target.

Most Popular